Cargando…

Real-World Health Care Resource Utilization and Costs Among US Patients with Knee Osteoarthritis Compared with Controls

PURPOSE: To determine the prevalence, healthcare resource utilization and costs (HCRU&C) of knee osteoarthritis (OA) patients versus controls. PATIENTS AND METHODS: Retrospective, matched-cohort administrative claims analysis using IBM MarketScan databases (2011–2017). Newly diagnosed, adult (18...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bedenbaugh, Angela V, Bonafede, Machaon, Marchlewicz, Elizabeth H, Lee, Vinson, Tambiah, Jeyanesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8153072/ https://www.ncbi.nlm.nih.gov/pubmed/34054301 http://dx.doi.org/10.2147/CEOR.S302289

Ejemplares similares

Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis
por: Bonafede, Machaon, et al.
Publicado: (2021)

Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure
por: Bonafede, Machaon, et al.
Publicado: (2018)

Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US
por: Bonafede, Machaon M, et al.
Publicado: (2013)

Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data
por: Gharaibeh, Mahdi, et al.
Publicado: (2020)

Short- and longer-term health-care resource utilization and costs associated with acute ischemic stroke
por: Johnson, Barbara H, et al.
Publicado: (2016)

Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial
por: Tambiah, Jeyanesh R. S., et al.
Publicado: (2021)

Healthcare resource utilization and costs among children with cystic fibrosis in the United States
por: Thorat, Teja, et al.
Publicado: (2021)

Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults
por: Polsky, Daniel, et al.
Publicado: (2012)

Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2021)

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting
por: Bonafede, Machaon, et al.
Publicado: (2013)

Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data
por: Paranagama, Dilan, et al.
Publicado: (2018)

Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States
por: Soliman, Ahmed M., et al.
Publicado: (2018)

Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis
por: Fox, Robert J., et al.
Publicado: (2022)

Cost-Effectiveness of Global Endometrial Ablation vs. Hysterectomy for Treatment of Abnormal Uterine Bleeding: US Commercial and Medicaid Payer Perspectives
por: Miller, Jeffrey D., et al.
Publicado: (2015)

Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States
por: Thorat, Teja, et al.
Publicado: (2021)

Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients
por: Johnson, Barbara H., et al.
Publicado: (2015)

Assessing the Association of Formulary Copayment Changes with Real-World Treatment Patterns in Patients with Rheumatoid Arthritis on Etanercept
por: Bonafede, Machaon, et al.
Publicado: (2020)

Lorecivivint, a Novel Intraarticular CDC‐like Kinase 2 and Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial
por: Yazici, Yusuf, et al.
Publicado: (2020)

Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database
por: Studer, Sean, et al.
Publicado: (2018)

Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
por: Cheng, Wendy Y., et al.
Publicado: (2021)

A Real-World Assessment of Outcomes, Health Resource Utilization, and Costs Associated with Cerebral Edema in US Patients with Large Hemispheric Infarction
por: Tsao, Nicole, et al.
Publicado: (2021)

Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study
por: Fineman, Mark S., et al.
Publicado: (2023)

Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs
por: Bonafede, Machaon M, et al.
Publicado: (2014)

Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera
por: Parasuraman, Shreekant V., et al.
Publicado: (2018)

Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
por: Moccia, Marcello, et al.
Publicado: (2022)

Medical costs associated with cardiovascular events among high-risk patients with hyperlipidemia
por: Bonafede, Machaon M, et al.
Publicado: (2015)

Cost effectiveness of endometrial ablation with the NovaSure(®) system versus other global ablation modalities and hysterectomy for treatment of abnormal uterine bleeding: US commercial and Medicaid payer perspectives
por: Miller, Jeffrey D, et al.
Publicado: (2015)

Value analysis of digital breast tomosynthesis for breast cancer screening in a commercially-insured US population
por: Bonafede, Machaon M, et al.
Publicado: (2015)

Recommended and real-world treatment of knee osteoarthritis in Korea: differences and compromises
por: Kim, Hyun-Sook
Publicado: (2019)

US Health Resource Utilization and Cost Burden Associated with Choroideremia
por: Dong, Shaobin, et al.
Publicado: (2021)

Resource utilization and treatment costs of patients with severe hemophilia A: Real‐world data from the ATHNdataset
por: Recht, Michael, et al.
Publicado: (2022)

EPH60 Real-World Data Dashboard Integrating Public Health & EHR Data for Identifying COVID-19 Vaccination Gaps in the US
por: Kallenbach, L, et al.
Publicado: (2022)

The direct and indirect costs of adult atopic dermatitis
por: Manjelievskaia, Janna, et al.
Publicado: (2021)

Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population
por: Bonafede, Machaon, et al.
Publicado: (2014)

Medication usage, treatment intensification, and medical cost in patients with type 2 diabetes: a retrospective database study
por: Bonafede, Machaon, et al.
Publicado: (2016)

Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study
por: Pawaskar, Manjiri, et al.
Publicado: (2013)

Real-World Healthcare Resource Utilization and Cost Burden Assessment for Adults With Generalized Myasthenia Gravis in the United States
por: Phillips, Glenn, et al.
Publicado: (2022)

Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women
por: Tran, Oth, et al.
Publicado: (2021)

S107. HEALTHCARE UTILIZATION AND COST IN SCHIZOPHRENIA AND BIPOLAR DISORDER: REAL-WORLD EVIDENCE FROM US CLAIMS DATABASES
por: Greene, Mallik, et al.
Publicado: (2018)

Correction to: Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women
por: Tran, Oth, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5mvveflk500m0q446lfr4n6t9e